The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
From machine learning to deep learning: progress in machine intelligence for rational drug discovery
Abstract
Machine intelligence, which is normally presented as artificial intelligence, refers to the intelligence exhibited by computers. In the history of rational drug discovery, various machine intelligence approaches have been applied to guide traditional experiments, which are expensive and time-consuming. Over the past several decades, machine-learning tools, such as quantitative structure-activity relationship (QSAR) modeling, were developed that can identify potential biological active molecules from millions of candidate compounds quickly and cheaply. However, when drug discovery moved into the era of 'big' data, machine learning approaches evolved into deep learning approaches, which are a more powerful and efficient way to deal with the massive amounts of data generated from modern drug discovery approaches. Here, we summarize the history of machine learning and provide insight into recently developed deep learning approaches and their applications in rational drug discovery. We suggest that this evolution of machine intelligence now provides a guide for early-stage drug design and discovery in the current big data era.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are various tasks in the drug discovery process where machine learning can be used to streamline the tasks. This includes drug compound property and activity prediction, de novo design of drug compounds, drug–receptor interactions, and drug reaction prediction [16].”
From The rise of artificial intelligence in healthcare applications (2020) · cites this paper as [16]
In the citing paper
“QSAR modeling methods, such as linear discriminant analysis (LDA), support vector machines (SVMs), random forest (RF), and decision trees, have been used to identify prospective drug candidates and have evolved into AI-based QSAR approaches can use that to speed up QSAR analysis”
From Blockchain and Artificial Intelligence Technology in E-Health (2021) · cites this paper as Zhang 2017 & Jain 2015
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
LeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
Learning representations by back-propagating errors
Rumelhart, D. E., Hinton, G. E., & Williams, R. J. (1986) · Nature · doi:10.1038/323533a0 · Cited by 31,892
Wu, Y., & Vapnik, V. N. (1999) · Technometrics · doi:10.2307/1271368 · Cited by 27,236
Deep learning in neural networks: an overview
Schmidhuber, J. (2015) · Neural Networks · doi:10.1016/j.neunet.2014.09.003 · Cited by 18,570
Eigenfaces vs. Fisherfaces: recognition using class specific linear projection
Belhumeur, P. N., Hespanha, J. P., & Kriegman, D. J. (1997) · IEEE Transactions on Pattern Analysis and Machine Intelligence · doi:10.1109/34.598228 · Cited by 11,798
An Introduction to Kernel and Nearest-Neighbor Nonparametric Regression
Altman, N. (1992) · The American Statistician · doi:10.1080/00031305.1992.10475879 · Cited by 5,657
Predicting the sequence specificities of DNA- and RNA-binding proteins by deep learning
Alipanahi, B., Delong, A., Weirauch, M. T., & Frey, B. J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3300 · Cited by 2,873
Bioisosterism: A Rational Approach in Drug Design
Patani, G. A., & LaVoie, E. J. (1996) · Chemical Reviews · doi:10.1021/cr950066q · Cited by 1,344
Big data deep learning: Challenges and perspectives
Chen, X.-W., & Lin, X. (2014) · IEEE Access · doi:10.1109/access.2014.2325029 · Cited by 1,255
Flagged first, then by citations
1 of the 60 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Hinton, 2006, 8, 1527
- Jain, 2015, In silico de novo design of novel NNRTIs: a bio-molecular modelling approach, RSC Adv., 5, 14814, 10.1039/C4RA15478A · DOI
- Unterthiner, 2014, Deep learning as an opportunity in virtual screening, Proc. Deep Learning Workshop NIPS
Cited by
Sorted by citations
Artificial intelligence in drug discovery and development
Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.010 · Cited by 1,695
The rise of artificial intelligence in healthcare applications
Bohr, A., & Memarzadeh, K. (2020) · Artificial Intelligence in Healthcare · doi:10.1016/b978-0-12-818438-7.00002-2 · Cited by 1,636
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
“Thus, the biggest question that arises in front of pharmaceutical companies is managing the cost and speed of the process [5].”
BackgroundNatural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery
Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P. P., Maroyi, A., & Dzobo, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061578 · Cited by 1,301
Drug discovery with explainable artificial intelligence
Jiménez-Luna, J., Grisoni, F., & Schneider, G. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-020-00236-4 · Cited by 1,063
Metadata
- Authors
- Zhang, L., Tan, J., Han, D., & Zhu, H.
- Affiliations
- Beijing University of Technology (CN)
- Rutgers, The State University of New Jersey (US)
- Corresponding author
- Tan, Jianjun
- Zhu, Hao
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 22
- Issue
- 11
- Pages
- 1680-1685
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2753588101
- Cited by
- 760
- References
- 60
- Citations by year
- 2026: 42 · 2025: 90 · 2024: 105 · 2023: 134 · 2022: 112 · 2021: 96 · 2020: 79 · 2019: 61 · 2018: 39 · 2017: 2
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Discovery Today (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Chinese Natural Science Foundation Project (21173014)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Materials Science › Materials Chemistry › Machine Learning in Materials Science
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- rational drug discovery, deep learning, machine learning, QSAR, big data, history of machine learning, computer-aided drug design
- MeSH terms
- Machine Learning, Artificial Intelligence, Humans, Models, Theoretical, Drug Design, Quantitative Structure-Activity Relationship, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
